LeMaitre Vascular Inc (LMAT)

Currency in USD
97.60
-2.73(-2.72%)
Closed·
97.12-0.48(-0.49%)
·
LMAT Scorecard
Full Analysis
Has raised its dividend for 14 consecutive years
LMAT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
97.49100.03
52 wk Range
71.42109.58
Key Statistics
Prev. Close
97.6
Open
99.76
Day's Range
97.49-100.03
52 wk Range
71.42-109.58
Volume
207.12K
Average Volume (3m)
159.32K
1-Year Change
6.47%
Book Value / Share
16.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LMAT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
104.78
Upside
+7.35%
Members' Sentiments
Bearish
Bullish
ProTips
6 analysts have revised their earnings upwards for the upcoming period

LeMaitre Vascular Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

LeMaitre Vascular Inc Company Profile

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

LeMaitre Vascular Inc SWOT Analysis


Niche Market Leade
LeMaitre Vascular dominates specialized vascular device segments, leveraging its position for consistent revenue growth and pricing powe
Financial Resilience
Explore LMAT's strong financial health, impressive profitability metrics, and 15-year dividend streak, despite recent margin pressures
Global Expansion
Delve into LeMaitre's strategic initiatives for international growth, particularly the promising RestoreFlow allograft business in Europe
Valuation Insights
Analyst targets range from $92 to $113, reflecting varied outlooks on LMAT's growth potential amid sector-wide multiple compression
Read full SWOT analysis

LeMaitre Vascular Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of $0.60 beat forecasts by 5.26%, with revenue of $64.2M exceeding expectations by 2.75%
  • Gross margin improved to 70%, up 110 basis points, driven by price increases and unit growth
  • Full-year revenue guidance raised to $251M, with EPS guidance increased to $2.30, reflecting 19% YoY growth
  • International expansion and new product launches identified as key strategic initiatives for future growth
  • Stock rose 1.47% in aftermarket trading, closing at $84.36, with analyst price targets ranging from $90 to $120
Last Updated: 05/08/2025, 23:24
Read Full Transcript

Compare LMAT to Peers and Sector

Metrics to compare
LMAT
Peers
Sector
Relationship
P/E Ratio
46.9x31.0x−0.6x
PEG Ratio
2.081.110.00
Price/Book
6.1x2.8x2.6x
Price / LTM Sales
9.4x3.7x3.3x
Upside (Analyst Target)
7.9%−5.9%39.0%
Fair Value Upside
Unlock−9.6%4.9%Unlock

Analyst Ratings

6 Buy
5 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 104.78
(+7.35% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.09%
Dividend Yield
0.82%
Industry Median 1.31%
Annualised payout
0.80
Paid quarterly
5-Years Growth
+14.87%
Growth Streak

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
0.60 / 0.57
Revenue / Forecast
64.20M / 62.48M
EPS Revisions
Last 90 days

LMAT Income Statement

People Also Watch

205.13
TEL
+0.06%
285.80
RMD
-2.70%
353.97
IESC
+3.77%
137.26
FI
-1.73%
258.36
POWL
-1.75%

FAQ

What Stock Exchange Does LeMaitre Vascular Trade On?

LeMaitre Vascular is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for LeMaitre Vascular?

The stock symbol for LeMaitre Vascular is "LMAT."

What Is the LeMaitre Vascular Market Cap?

As of today, LeMaitre Vascular market cap is 2.21B.

What Is LeMaitre Vascular's Earnings Per Share (TTM)?

The LeMaitre Vascular EPS (TTM) is 2.09.

When Is the Next LeMaitre Vascular Earnings Date?

LeMaitre Vascular will release its next earnings report on 29 Oct 2025.

From a Technical Analysis Perspective, Is LMAT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has LeMaitre Vascular Stock Split?

LeMaitre Vascular has split 0 times.

How Many Employees Does LeMaitre Vascular Have?

LeMaitre Vascular has 658 employees.

What is the current trading status of LeMaitre Vascular (LMAT)?

As of 26 Aug 2025, LeMaitre Vascular (LMAT) is trading at a price of 97.60, with a previous close of 97.60. The stock has fluctuated within a day range of 97.49 to 100.03, while its 52-week range spans from 71.42 to 109.58.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.